Evidence reviewed: 8 November 2026. Heart failure (HF) is a clinical syndrome in which heart abnormalities cause symptoms such as breathlessness, fatigue, poor exercise tolerance or fluid congestion. It does not mean that the heart has stopped, and a normal-looking ejection fraction does not exclude it. Treatments have evolved substantially: the 2026 European Society of Cardiology (ESC) guideline introduces a new ejection-fraction classification and recommends SGLT2 inhibitors and mineralocorticoid receptor antagonists as foundational treatment across symptomatic HF phenotypes, when suitable [1,2].
What is heart failure?
Heart failure occurs when structural or functional abnormalities of the heart cause symptoms or signs associated with inadequate forward blood flow, elevated filling pressures, or both. Common causes include coronary artery disease and previous heart attack, hypertension, cardiomyopathy, valvular disease, certain arrhythmias and some drugs or systemic illnesses. The resulting changes may activate the sympathetic nervous system and renin–angiotensin–aldosterone system, causing fluid retention, higher cardiac workload and adverse remodeling [1,3].
The condition can be chronic, stable with appropriate treatment, or decompensated when symptoms and congestion worsen. Some patients have significant disease without swollen ankles, and other illnesses can cause breathlessness and edema without HF; an individualized assessment is essential.
Symptoms and signs to recognize
- Shortness of breath during exercise or routine daily activities.
- Orthopnea: difficulty breathing when lying flat, sometimes relieved by extra pillows.
- Paroxysmal nocturnal dyspnea: waking breathless after sleeping.
- Fatigue or reduced exercise capacity and general weakness.
- Leg, ankle or abdominal swelling from fluid accumulation.
- Rapid weight gain from fluid retention in some patients, or reduced appetite and abdominal fullness.
Seek emergency care immediately for severe breathlessness at rest, new chest pain, fainting, blue or gray lips, new confusion, or coughing pink frothy sputum. Rapidly worsening symptoms can indicate acute pulmonary edema, an acute coronary syndrome or dangerous arrhythmia. Do not self-increase medicines or wait for a scheduled appointment in a serious emergency.
How is heart failure diagnosed?
A clinician reviews symptoms, medical history, blood pressure, pulse, signs of congestion and possible causes. Common tests include:
- Echocardiography: evaluates left ventricular ejection fraction (LVEF), heart structure, valves, diastolic function and other findings.
- BNP or NT-proBNP: natriuretic peptide biomarkers that support diagnosis or exclusion in appropriate clinical settings, but must be interpreted alongside age, kidney function, obesity and rhythm.
- Electrocardiogram: identifies rhythm disturbances or evidence suggesting an underlying cardiac problem.
- Blood tests: kidney function, potassium and sodium, blood count, iron studies and other tests based on likely causes and treatment risks.
- Chest X-ray or additional imaging: selected when clinically indicated to assess congestion or alternative diagnoses.
No single ejection-fraction value or BNP number establishes the diagnosis alone. The 2026 ESC guidance emphasizes the combination of symptoms, objective cardiac evidence and etiological evaluation to identify potentially treatable causes [1].
ACC/AHA stages A to D
Stages describe the progression of underlying heart-failure risk and disease, rather than how breathless someone feels at a particular moment. The stage framework is shared across major guidelines [1,3].
| Stage | Meaning | Typical clinical priorities |
|---|---|---|
| A: At risk | Risk factors such as diabetes, hypertension or coronary disease but no HF symptoms or structural cardiac abnormalities. | Prevent disease through risk-factor treatment, smoking cessation, appropriate exercise and indicated cardiometabolic therapy. |
| B: Pre-HF | Structural or functional abnormalities or other objective evidence of heart disease, but no current or prior HF symptoms. | Treat the cause and use appropriate therapies for selected patients with impaired heart function or previous heart attack. |
| C: Symptomatic HF | Cardiac disease with current or previous signs or symptoms of HF. | Foundational medication, congestion treatment, monitoring, rehabilitation and cause-specific care. |
| D: Advanced HF | Severe, persistent or recurrent problems despite appropriate treatment. | Specialist evaluation for advanced treatment, symptom-focused care and shared planning. |
Stage C does not necessarily mean severe end-stage disease. Patients may remain stable for years with appropriately selected therapies. Advanced disease can occur even with a preserved ejection fraction [1].
NYHA functional class is different from stage
The New York Heart Association (NYHA) classes describe the degree to which physical activity causes symptoms:
| NYHA class | Functional limitation |
|---|---|
| I | Ordinary activity causes no undue breathlessness, fatigue or palpitations. |
| II | Ordinary activity produces symptoms; comfortable at rest. |
| III | Less-than-ordinary activity produces symptoms; comfortable at rest. |
| IV | Symptoms may occur at rest and physical activity causes discomfort. |
Functional class can improve or worsen with treatment or exacerbation; stage and class are not interchangeable.
Important 2026 ESC change: ejection-fraction categories
Definitions differ between the 2026 ESC and the US ACC/AHA/HFSA frameworks. The 2026 ESC guideline removes the prior HF with mildly reduced EF (HFmrEF) category and defines two main symptomatic phenotypes [1]:
- ESC 2026 HFrEF: left ventricular ejection fraction below 50%, with HF signs and/or symptoms.
- ESC 2026 HFpEF: ejection fraction 50% or higher, with symptoms/signs and objective cardiac structural or functional abnormalities.
By contrast, the 2022 ACC/AHA/HFSA guideline has continued to describe HFrEF as LVEF 40% or lower, HFmrEF as 41–49%, and HFpEF as 50% or greater [3]. These differences reflect guideline evolution; readers should not assume the old categories are universal or that ‘preserved EF’ means a normal heart. The specific care pathway depends on the guideline, clinical findings and treatment evidence.
Foundational treatment for symptomatic heart failure
The 2026 ESC guideline places strong emphasis on early, coordinated introduction of treatments that reduce hospitalization and/or death, with subsequent dose optimization and laboratory monitoring [1]. For HFrEF under the 2026 ESC classification, foundational medical therapy includes the following groups when clinically appropriate:
| Drug group | Examples and purpose | Safety checks |
|---|---|---|
| ARNI or ACE inhibitor (ARB if intolerance) | Sacubitril/valsartan, or an ACE inhibitor/ARB when appropriate; reduce maladaptive neurohormonal effects and improve outcomes. | Blood pressure, kidney function, potassium; pregnancy contraindications; avoid simultaneous ACE inhibitor with ARNI. |
| Evidence-based beta-blocker | Bisoprolol, carvedilol or metoprolol succinate in eligible patients; reduce sympathetic effects and improve survival. | Heart rate, blood pressure, congestion and tolerability; start and titrate carefully. |
| Mineralocorticoid receptor antagonist (MRA) | Spironolactone or eplerenone for eligible HFrEF patients; an appropriate steroidal or nonsteroidal MRA may be used for other phenotypes under updated guidance. | Potassium and renal function; avoid clinically important hyperkalemia. |
| SGLT2 inhibitor | Dapagliflozin or empagliflozin reduce HF events in symptomatic eligible patients, including many without diabetes. | Kidney function, volume status, genital infections and ketoacidosis precautions; treatment interruptions during serious acute illness may be necessary. |
Selection and dosing are not interchangeable; contraindications, blood pressure, renal function, potassium, frailty and other diagnoses guide therapy. Do not start four medicines at once without a clinician-directed plan, but equally do not assume that a stable patient must remain on only one class for months when guideline-directed treatment is appropriate.
How is HF with preserved EF treated?
HFpEF requires treatment of congestion, hypertension, atrial fibrillation, obesity, diabetes, kidney disease, sleep apnea and other contributors. The 2026 ESC guideline recommends SGLT2 inhibitors and MRAs as foundational therapy in eligible symptomatic patients regardless of LVEF. In HFpEF, the SGLT2 inhibitor evidence for the composite outcome is driven particularly by fewer heart-failure hospitalizations, not proof of equal mortality reduction across every EF category [1].
Other therapy is tailored to symptoms, etiology and comorbidities. A preserved EF does not justify withholding evidence-based treatment, but the exact benefit from different drug classes varies by phenotype and patient risk.
Diuretics relieve congestion, but their role is different
Loop diuretics such as furosemide or torsemide help reduce fluid overload, edema and breathlessness. They are titrated to fluid status and tolerability, with monitoring of kidney function, sodium and potassium. Diuretics improve congestion but are not substitutes for therapies shown to alter long-term outcomes. A sudden change in weight or swelling should prompt contact with the care team according to an individualized action plan, not automatic unsupervised dose escalation [1,3].
Acute decompensated heart failure
Severe breathlessness, pulmonary edema, poor perfusion or marked fluid overload requires urgent assessment. Hospital treatment may involve oxygen when hypoxemic, intravenous diuretics, noninvasive respiratory support, evaluation for myocardial ischemia or arrhythmia, and selected vasoactive therapy when clinically indicated. Routine inotropes are not indicated for every hospitalized HF patient because they may cause serious arrhythmias or other harms. Evaluation should identify the trigger, such as infection, new atrial fibrillation, uncontrolled blood pressure, ischemia or missed medication.
Device therapy and advanced options
For selected patients, an implantable cardioverter-defibrillator (ICD) may prevent sudden arrhythmic death and cardiac resynchronization therapy (CRT) may benefit those with particular conduction abnormalities and reduced EF despite appropriate medical therapy. Decisions depend on EF, QRS duration/morphology, symptoms, etiology, expected survival and time on therapy, not an EF number alone. Selected advanced patients may benefit from specialist assessment for mechanical circulatory support or heart transplantation. Palliative care can accompany active HF treatment to improve symptoms and planning at any stage when needed [1,3].
Monitoring and living with heart failure
- Take medicines as prescribed and maintain a current medication list.
- Monitor symptoms and weight if recommended, and agree on thresholds for contacting the clinical team.
- Keep follow-up appointments for blood pressure, kidney function, potassium, medication titration and response.
- Reduce excess sodium and follow an individualized nutrition plan; rigid fluid restriction is not appropriate for every person.
- Stay physically active within a safe plan, including cardiac rehabilitation when available and indicated.
- Manage other conditions, including diabetes, atrial fibrillation, coronary disease, sleep problems and anemia or iron deficiency.
- Review medicines that can worsen HF, including certain NSAIDs and some other agents, with a healthcare professional.
Frequently asked questions
Can someone have heart failure with a normal ejection fraction?
Yes. HFpEF requires symptoms plus objective evidence of cardiac dysfunction or structural abnormalities; EF alone is insufficient [1].
Does stage D mean the person must have an EF below 20%?
No. Advanced HF can arise with different EF values and is assessed by persistent severe clinical problems, hospitalization, tolerance of treatment and other criteria.
What changed in the 2026 ESC guideline?
The HFmrEF category was removed; HFrEF now includes LVEF below 50%, and MRAs and SGLT2 inhibitors are recommended foundational therapy across symptomatic EF phenotypes when eligible [1].
Should I stop a medicine once I feel better?
Not without a clinician. Improvement may reflect treatment benefit, and withdrawal can lead to deterioration. HF with improved EF often still requires ongoing guideline-directed care [3].
Can I increase my diuretic when ankles swell?
Follow only the specific dose-adjustment plan provided by your care team; otherwise contact your clinician, because electrolyte and kidney complications are possible.
Key takeaways
Use the stage, symptom burden and confirmed cardiac phenotype to guide HF care. The 2026 ESC guidance revises EF categories and strengthens foundational therapy; timely diagnosis, treatment of causes, safe medication titration and individualized monitoring improve outcomes.
References
- European Society of Cardiology. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;47:5346–5504. doi:10.1093/eurheartj/ehag100.
- European Society of Cardiology. 2026 ESC heart failure guideline: new classification and recommendations. 29 August 2026.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145:e895–e1032. doi:10.1161/CIR.0000000000001063.
Medical disclaimer: Educational information, not an individualized treatment plan. Heart failure medicines require clinician-directed prescribing and monitoring. Severe breathlessness, chest pain, fainting or new confusion requires emergency medical assessment.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.